Register Login
Register to leave comments
  • News bot March 26, 2026, 11:05 a.m.

    📋 ACUMEN PHARMACEUTICALS, INC. (ABOS) - Financial Results

    Filing Date: 2026-03-26

    Accepted: 2026-03-26 07:04:37

    Event Type: Financial Results

    Event Details:

    ACUMEN PHARMACEUTICALS, INC. (ABOS) Reports the reporting period Financial Results ACUMEN PHARMACEUTICALS, INC. (ABOS) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 172077
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 54220
      • Expect to report topline results for ALTITUDE
      • AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026
      • Lead clinical candidate IND filing in Acumen’s Enhanced Brain Delivery (EBDTM) program targeted for mid
        • targeting the submission of an IND filing with respect to a lead clinical candidate in its EBD program in mid-2027
        • targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com. About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. JCR continues to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. JCR’s innovative therapies address conditions like growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. JCR is also developing treatments for rare diseases like MPS I, MPS II, MPS IIIA and B, and more.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995
        • targeting blood-brain barrier-penetrating therapy,” said Daniel O’Connell, Chief Executive Officer of Acumen. “2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2025 2024 Change ($) Change (%)
    Current Assets Prepaid Expenses Other Current Assets 5.39K 6.75K $-1.36K -20.18%
    Current Liabilities Accounts Payable 554.00 554.00 $0.00 +0.00%
    Operating Expenses Loss From Operations -123.83K -114.02K $-9.81K -8.61%
    Other Income Expense Interest Income 7.45K 14.32K $-6.87K -47.98%
    Other Income Expense Interest Expense -4.22K -4.07K $-156.00 -3.83%
    Other Income Expense Net Loss -121.33K -102.33K $-19.01K -18.57%
    Other Comprehensive Gain Loss Net Loss Per Share -2.00 -2.00 $0.00 +0.00%
    Cash Flows From Operating Activities Net Loss -121.33K -121.33K $0.00 +0.00%
    Changes In Operating Assets And Liabilities Prepaid Expenses Other Current Assets 1.36K -3.66K $5.02K +137.25%
    Changes In Operating Assets And Liabilities Accounts Payable -5.09K 4.27K $-9.36K -219.33%
    Prepaid Expenses and Other Current Assets 5.39K 6.75K $-1.36K -20.18%
    Other Assets 350.00 486.00 $-136.00 -27.98%
    Accounts Payable 554.00 554.00 $0.00 +0.00%
    Loss from Operations -123.83K -114.02K $-9.81K -8.61%
    Interest Income 7.45K 14.32K $-6.87K -47.98%
    Interest Expense -4.22K -4.07K $-156.00 -3.83%
    Net Loss -121.33K -102.33K $-19.01K -18.57%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ACUMEN PHARMACEUTICALS, INC.
    • Ticker Symbol: ABOS

Search

News categories